RxDoctor Payments Data

Joseph Lee, MD

Cardiovascular Disease · Glendale, CANPI 1952497521

Payments from drug & device makers

$32,072in general payments, 2019–2025

Across 980 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$8K
  • Boston Scientific$4K
  • Abbott$2K
  • Novartis$2K
  • Amgen$2K
  • AstraZeneca$2K
  • plus $12K from 38 others

What the payments were for

  • Consulting fees$8,39726%
  • Travel & lodging$2341%
  • Food & beverage$23,40173%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,072 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$544,871
Medicare patients
1,455
Services billed
4,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban609$596,555
EntrestoSacubitril/Valsartan231$238,066
Repatha SureclickEvolocumab289$211,048
XareltoRivaroxaban80$77,455
JardianceEmpagliflozin72$65,258
BrilintaTicagrelor88$55,594
Praluent PenAlirocumab57$41,617
FarxigaDapagliflozin Propanediol47$40,042
VascepaIcosapent Ethyl71$39,862
Coreg CrCarvedilol Phosphate15$20,591
MultaqDronedarone Hcl13$19,399
Telmisartan719$16,801
Rosuvastatin Calcium1,252$16,375
OzempicSemaglutide13$14,178
Icosapent Ethyl44$11,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,189$596,555609 claims
NovartisEntresto$2,253$238,066231 claims
AstraZenecaBrilinta, Farxiga$1,604$95,636135 claims
Johnson & JohnsonXarelto$834$77,45580 claims
Boehringer IngelheimJardiance$1,127$65,25872 claims
Sanofi-aventis U.S. LLCMultaq$253$19,39913 claims
Novo NordiskOzempic$182$14,17813 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$170$13,30338 claims
Esperion Therapeutics, Inc.Nexlizet$335$11,06716 claims
Kowa Pharmaceuticals America, Inc.Livalo$270$8,10316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →